Summary: In insulin-treated adults with type 2 diabetes and beta-cell dysfunction, adding multistrain probiotics plus omega-3 fatty acids produced only a borderline within-group rise in beta-cell function and no significant advantage over placebo on adjusted analysis, despite favourable trends in glucose, insulin sensitivity, and TNF-alpha.
PICO Summary
| Element | Detail |
|---|---|
| Population | 45 adults with type 2 diabetes and beta-cell dysfunction (%B <50%) on insulin, alone or with oral agents (secondary analysis). |
| Intervention | Live multistrain probiotic co-supplemented with omega-3 PUFAs. |
| Comparison | Placebo, no active supplementation. |
| Outcome | Within-group %B rose 42.2 ± 15.4 to 62.2 ± 34.0 (p=0.049, wide variance), but adjusted ANCOVA showed no significant difference versus placebo. Secondary falls in fasting glucose and TNF-alpha and improved insulin sensitivity. No adverse effects. |
Probiotic + omega-3 vs placebo on beta-cell function in T2D
RCT secondary analysis · type 2 diabetes
The within-group rise in beta-cell function was only borderline and disappeared after adjustment, with no significant advantage over placebo. Safe, but not a beta-cell therapy on this evidence.
Expert Commentary
The promise of restoring beta-cell function with something as benign as a probiotic and fish oil is seductive, which is exactly why I read the statistics here carefully rather than the abstract’s optimism. My verdict is negative on the headline claim, and I think the data support that plainly. The within-group rise in %B was borderline at p equals 0.049 with enormous variability, and crucially the properly adjusted comparison against placebo found no significant difference, the pattern I associate with regression to the mean or chance in a small, underpowered study. The supportive moves in fasting glucose and TNF-alpha are encouraging mechanistically but do not rescue a null primary outcome. Can I use this with my patients? Not as a beta-cell therapy, and I would gently correct any patient who believed it was one. The combination looks safe, so if someone already takes these supplements I have no reason to stop them, provided they never displace glycaemic optimisation, weight management, and agents with proven benefit. I would want a properly powered trial before treating this as anything more than a harmless adjunct.
References
Savytska M, Kyriienko D, Mykhalchyshyn G, Tsyryuk O, Falalyeyeva T, Kobyliak N. Efficacy of probiotic co-supplementation with omega-3 PUFAs on pancreatic beta-cell function in type 2 diabetes. Sci Rep. 2025;15(1):33870. doi:10.1038/s41598-025-07861-2